Genocea Biosciences (GNCA) Tops Q3 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- Exclusive-Silver Lake in talks to buy Workday, sources say
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Citi agrees to acquire rewards platform Kard Financial
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Total darkness, then sunset as full eclipse wows spectators in Spain
Genocea Reports Third Quarter 2015 Financial Results
November 5, 2015 7:30 AM EST- Company Reports Recent Milestones and Announces Expansion of ATLASTM Technology into Immuno-Oncology -
- Conference Call and Webcast Scheduled for 9:00 a.m. ET Today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today reported recent corporate highlights and financial results for the third quarter ended September 30, 2015.
In early... More
Genocea Announces Immuno-Oncology Research Collaboration with Memorial Sloan Kettering Cancer Center
November 5, 2015 7:00 AM EST- Goal is to Utilize ATLASTM to Discover Biologically Relevant Neoantigens for Vaccine Development -
- Company to Discuss Collaboration and Oncology Strategy on Third Quarter 2015 Earnings Call at 9am ET Today -
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, today announced a collaboration with Memorial Sloan Kettering Cancer Center to screen the T cell responses of melanoma and non-small cell lung cancer patients treated with checkpoint inhibitors (CPI) against the complete repertoire of patient-specific putative... More
